<!DOCTYPE html>
<!-- saved from url=(0071)http://localhost:8080/smbms_war_exploded/jsp/MatchServlet.do?sampleId=5 -->
<html><head lang="en"><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
    
    <title>Precision Medicine Matching System</title>
    <link type="text/css" rel="stylesheet" href="./Precision Medicine Matching System_files/style.css">
    <link type="text/css" rel="stylesheet" href="./Precision Medicine Matching System_files/public.css">
<link href="./Precision Medicine Matching System_files/WdatePicker.css" rel="stylesheet" type="text/css"></head>
<body class="vsc-initialized">
<!--头部-->
    <header class="publicHeader">
        <h1>Precision Medicine Matching System</h1>
        <div class="publicHeaderR">
            <p><span>Hello</span><span style="color: #fff21b"> admin</span> ,welcome! </p>
            <a href="http://localhost:8080/smbms_war_exploded/jsp/logout.do">Logout</a>
        </div>
    </header>
 <section class="publicMian ">
     <div class="left">
         <h2 class="leftH2"><span class="span1"></span> List <span></span></h2>
         <nav>
             <ul class="list">
                 <li><a href="http://localhost:8080/smbms_war_exploded/jsp/drug.do?method=getDrug">Drug List</a></li>
                 <li><a href="http://localhost:8080/smbms_war_exploded/jsp/upload.jsp">Upload</a></li>
                 <li><a href="http://localhost:8080/smbms_war_exploded/jsp/ListFileServlet.do">Sample</a></li>
                 <li><a href="http://localhost:8080/smbms_war_exploded/jsp/user.do?method=getUserList">User List</a></li>
                 <li><a href="http://localhost:8080/smbms_war_exploded/jsp/pwdmodify.jsp">Password</a></li>
                 <li><a href="http://localhost:8080/smbms_war_exploded/jsp/logout.do">Quit</a></li>
             </ul>
         </nav>
     </div>
     <input type="hidden" id="path" name="path" value="/smbms_war_exploded">
     <input type="hidden" id="referer" name="referer" value="http://localhost:8080/smbms_war_exploded/jsp/ListFileServlet.do">
<div class="right">
    <div class="location">
        <strong>Now you are at:</strong>
        <span>Match Result</span>
    </div>
    <div class="search">
        <form method="get" action="http://localhost:8080/smbms_war_exploded/jsp/">
            <input name="method" value="query" class="input-text" type="hidden">
            
        </form>
    </div>

        <!--用户-->
    <table class="providerTable" cellpadding="0" cellspacing="0">
        <tbody><tr class="firstTr">
            <th width="20%">Name</th>
            <th width="20%">Source</th>
            <th width="60%">Summary</th>

        </tr>
        
            <tr>
                <td>
                    <span>PA166104775</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Although the atorvastatin (LIPITOR) drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (LDLR); one of the drug's mechanisms of action is increasing LDLR cell surface expression.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104776</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Warfarin (COUMADIN) is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillation and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (PROC) or protein S (PROS1) have been associated with tissue necrosis following warfarin administration.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104779</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for indacaterol (Hirobriz Breezhaler) does not contain pharmacogenetic information, but does contain information regarding the pharmacodynamics of the drug as a beta2-adrenoceptor (ADRB2) agonist and also contains information regarding the pharmackinetics of indacaterol involving UGT1A1, CYP3A4 and ABCB1.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104782</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for azathioprine (IMURAN) states to consider genotyping or phenotyping patients for TPMT deficiency and genotyping for NUDT15 deficiency in patients with severe myelosuppression. Alternative therapy in patients with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency should be considered.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104783</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for rasburicase (Elitek) states that is unclear whether patients with NADH cytochrome b5 reductase (<em>CYB5R1, 2, 3, 4</em>) deficiency are at risk for methemoglobinemia or hemolytic anemia. It also states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104785</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Erlotinib (TARCEVA) is a kinase inhibitor indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104786</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for chloroquine (ARALAN) states that it may cause hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. However, CDC guidelines from 2019 recommend chloroquine for malaria prophylaxis in patients who cannot be treated with primaquine or tafenoquine due to G6PD deficiency. The CDC <a rel="noopener noreferrer" href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html" target="_blank">Information for Clinicians on Therapeutic Options for COVID-19 Patients</a> discusses chloroquine but does not discuss testing for G6PD deficiency in this context.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104789</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104790</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The decision of whether to treat patients with imatinib (GLEEVEC) is based on the presence of genetic biomarkers, including BCR-ABL (the Philadelphia chromosome), KIT, and PDGFR gene rearrangements.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104791</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (<em>ERBB2</em>). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104792</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Fulvestrant (FASLODEX) is used to treat hormone-receptor positive breast cancer.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104794</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Sodium phenylacetate and sodium benzoate (AMMONUL) provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104795</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for busulfan (MYLERAN) states it is less effective in patients with chronic myelogenous leukemia who lack the Philadelphia chromosome.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104798</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for propranolol (INNOPRAN XL) states that no difference in clearance of the drug was observed between CYP2D6 extensive and poor metabolizers.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104800</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for indacaterol (ARCAPTA NEOHALER) states that steady-state AUC and Cmax of indacaterol were 1.2-fold higher in patients with the (TA)7/(TA)7 (*28/*28) genotype than in patients with the (TA)6/(TA)6 (*1/*1) genotype, suggesting no relevant effect of UGT1A1 genotype of indacaterol exposure.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104809</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for panitumumab (Vectibix) states that it is an EGFR antagonist indicated for the treatment of wild-type <em>RAS</em> (defined as wild-type in both <em>KRAS</em> and <em>NRAS</em>) metastatic colorectal cancer.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104810</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for mercaptopurine (PURIXAN) states that patients with severe myelosuppression should be evaluated for TPMT or NUDT15 deficiency, and that patients with homozygous TPMT or NUDT15 deficiency require substantial dose reductions.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104823</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for methylthioninium chloride Proveblue (also known as methylene blue) states that the drug is contraindicated in patients with G6PD deficiency due to risk of hemolytic anemia, and in patients with a deficiency in NADPH reductase (encoded by the <em>BLVRB</em> gene). The label also states that failure to respond to the drug may indicate a deficiency in cytochrome b5 reductase (CYB5R3) or G6PD.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104826</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Cetuximab (ERBITUX) is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of head and neck cancer, as well as K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved text.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104835</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Fluoxetine (PROZAC) is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder, obsessive compulsive disorder, bulimia nervosa, and panic disorder. Fluoxetine is metabolized by several cytochrome P450 enzymes with CYP2D6 being a major contributor.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104838</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for thioguanine (TABLOID) says to consider testing for TPMT and NUDT15 deficiency in patients who experience severe bone marrow toxicities or repeated episodes of myelosuppression. It also says to reduce initial dosage in patients known to have homozygous TPMT or NUDT15 deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104839</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug labels for aripiprazole (ABILIFY and ABILIFY MAINTENA), provide dosage adjustments for patients who are CYP2D6 poor metabolizers (PMs). CYP2D6 PMs taking ABILIFY should receive half the usual dose, and CYP2D6 PMs taking ABILIFY MAINTENA should have their dose reduced to 300 mg from the recommended dose of 400 mg.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104842</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Nilotinib (Tasigna) is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104844</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for erlotinib (Tarceva) states that it is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations, and switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy, among other indications.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104845</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for dapsone gel (ACZONE) states that some subjects with G6PD deficiency using ACZONE developed laboratory changes suggestive of hemolysis. The label states that dapsone gel (ACZONE) should be avoided in patients with congenital methemoglobinemia, which is associated with variants in CYB5R3.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104846</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for arsenic trioxide (TRISONEX) contains information regarding indication of the drug in patients whose acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104853</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for cisplatin states that genetic factors, such as variants in the TPMT gene, may contribute to cisplatin-induced ototoxicity. However, this association has not be consistent across populations and study designs.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104858</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Vemurafenib (ZELBORAF) is a kinase inhibitor used to treat patients with unresectable or metastatic melanoma in cases where the BRAF V600E mutation is found by an FDA-approved test.  <em>In vitro</em> evidence points to BRAF wild-type cells proliferation with exposure to BRAF inhibitors. Therefore, testing is required.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104863</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for dexlansoprazole (DEXILANT) notes that systemic exposure of the drug is generally higher in CYP2C19 intermediate and poor metabolizers, as compared to extensive metabolizers.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104866</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for pravastatin (PRAVACHOL) contains pharmacogenetic information regarding response results in patients with APOE genotype E2/E2 and Fredrickson Type III dysbetalipoproteinemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104874</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Sulfamethoxazole and trimethoprim (BACTRIM) is used to prevent and treat infections caused by certain bacteria. The label warns that hemolysis may occur in G6PD deficient individuals. It also notes that patients who are "slow acetylators" may be more prone to idiosyncratic reactions to sulfonamides. Acetylation status of an individual can be determined by examining variants in the <em>NAT2</em> gene. However, the label never mentions any specific gene with regard to acetylator status.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104876</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for primaquine states that G6PD testing has to be performed before using the drug, and that it should not be prescribed for patients with severe G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104878</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for methylene blue (PROVAYBLUE) states that it is contraindicated in patients with G6PD deficiency due to the risks of hemolytic anemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104881</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for glibenclamide (glyburide; GLYNASE PresTab) notes that caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104885</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Norfloxacin (NOROXIN) is used to treat urinary tract infections, sexually transmitted diseases and prostatitis caused by certain microorganisms.  The label reports hemolytic reactions have been seen in G6PD deficient individuals in association with this drug.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104889</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Pertuzumab (PERJETA) is a targeted antibody drug designed to bind to ERBB2 (HER2). Detection of HER2 protein overexpression is necessary for selection of patients appropriate for PERJETA therapy because these are the only patients studied and for whom benefit has been shown.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104891</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Nalidixic acid (NegGram) is used to treat urinary tract infections due to gram-negative bacteria.  Although the nalidixic acid drug label does not specifically mention genetic testing, the FDA highlight precaution prior to initiating treatment with nalidixic acid for G6PD deficient individuals due to an association with hemolytic anemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104892</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Sulfasalazine (Azulfidine) is used to treat and prolong remission for ulcerative colitis. The label warns that people with G6PD are susceptible to hemolytic anemia on this drug. The label also notes that acetylator status may affect metabolism of the drug and risk for adverse events; acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to inactivator or acetylator status.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104894</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for rasburicase (Fasturtec) states that it is contraindicated in patients with G6PD deficiency due to a risk of hemolytic anemia or methemoglobinemia. Testing or screening for G6PD deficiency is not mentioned.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104895</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Erythromycin ethylsuccinate and sulfisoxazole acetyl is used to treat acute otitis media in children caused by certain strains of <em>Haemophilus influenzae</em>.  The label warns that hemolysis may occur in G6PD deficient patients on this drug.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104897</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy.  Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104899</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for aripiprazole (Abilify Maintena) states that the starting and maintenance dose should be 300 mg in known CYP2D6 poor metabolizers. The EMA EPAR for aripiprazole (ABILIFY) states that the mean elimination half-life for the drug is approximately 75 hours in CYP2D6 extensive metabolizers and 146 hours in CYP2D6 poor metabolizers, but does not provide any dosing advice based on CYP2D6 metabolizer status.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104900</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for pegloticase (KRYSTEXXA) states that patients at risk for G6PD deficiency should be screened prior to starting treatment, and that the drug should not be administered to patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104902</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Sulfadiazine (SILVADENE) is an antimicrobial topical drug used to prevent and treat wound sepsis in second and third degree burns. A link between sulfadiazine-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section of the label.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104903</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Nitrofurantion (Furadantin) is used to treat urinary tract infections caused by certain strains of bacteria.  A link between nitrofurantoin-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104906</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Probenecid is used to treat chronic gouty arthritis.  An association between probenecid-induced hemolytic anemia and G6PD deficiency is highlighted in the Adverse Reactions section of the probenecid label.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104907</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) states that caution should be taken when administering eltrombopag in patients with known risk factors for thromboembolism, including Factor V Leiden (F5 gene) and ATIII deficiency (SERPINC1 gene).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104908</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for cetuximab (Erbitux) states that it is indicated for patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer, among other indications.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104912</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for eltrombopag (PROMACTA) notes that patients taking the drug have an increased risk of thromboembolism if they have antithrombin III deficiency (SERPINC1) or Factor V Leiden (F5). The label also mentions that when patients were evaluated for cytogenetic abnormalities in PROMACTA D1-M6 cohort, some patients had loss of chromosome 7 or deletion of chromosome 13.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104926</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRα rearrangements.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166104930</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for gefitinib (IRESSA) states that it is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105023</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for rosuvastatin (CRESTOR) states that higher plasma concentrations of the drug have been seen in small groups of patients homozygous for the <em>SLCO1B1</em> rs4149056 variant.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105070</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Anastrozole (ARIMIDEX) is an aromatase inhibitor indicated for use in postmenopausal women as an adjuvant treatment for hormone receptor-positive early breast cancer, as a first-line treatment for hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer, or to treat advanced breast cancer with disease progression following tamoxifen therapy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105147</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for glimepiride (AMARYL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the <em>G6PD</em> gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105148</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for glipizide (GLUCOTROL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the <em>G6PD</em> gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105178</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105195</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Metoclopramide (reglan) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The FDA-approved drug label for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide. The label and FDA table also mention G6PD;  patients with G6PD deficiency experiencing metoclopramide-induced methemoglobinemia should not be given methylene blue.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105211</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ondansetron (ZOFRAN) states that the drug is a substrate for CYP2D6 (among other CYP enzymes), but is likely that CYP2D6 genetic deficiency will result in little change in the rate of ondansetron elimination.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105213</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for oxcarbazepine (OXTELLAR XR) states that testing for the presence of the HLA-B*1502 allele should be considered in patients with ancestry in genetically at-risk populations prior to initiating treatment with the drug, due to the risk for Stevens-Johnson syndrome or toxic epidermal necrolysis.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105232</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for quinine (QUALAQUIN) previously had language to contraindicate the drug in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This contraindication was removed in 6/2019 and replaced with language recommending monitoring for hemolytic anemia during treatment. The label also mentions CYP2D6 poor metabolizers in the context of drug-drug interactions with desipramine.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166105334</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for nilotinib (Tasigna) states it is indicated for patients who have Philadelphia chromosome-positive (presence of a BCR-ABL1 gene fusion) chronic myelogenous leukemia (CML). The label differs from that of the FDA as it does not contain any information regarding UGT1A1 genotype.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114317</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Sodium phenylbutyrate (BUPHENYL) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114381</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for sodium phenylbutyrate (AMMONAPS) states that it is indicated as an adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase (<em>CPS1</em>), ornithine transcarbamylase (<em>OTC</em>) or argininosuccinate synthetase (<em>ASS1</em>).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114382</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for ticagrelor (Brilique) contains information regarding a study in which CYP2C19 and ABCB1 genotyping was carried out (PLATO - platelet inhibition and patient outcomes). In patients with one or more CYP2C19 loss of function allele, non-coronary artery by-pass grafting (non-CABG) PLATO major bleeding was increased when treated with ticagrelor compared to clopidogrel, but was similar in patients with no loss of function alleles.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114482</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for vemurafenib (Zelboraf) requires testing of tumours for the BRAF V600 mutation prior to initiating treatment.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114903</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Afatinib (GILOTRIF) is indicated for patients with metastatic non-small cell lung cancer (NSCLC) who have tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114905</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Belimumab (BENLYSTA) is a human IgG1lambda monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114907</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for bosutinib (BOSULIF) notes that it is intended for adults with newly-diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) or chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114908</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Carglumic acid (Carbaglu) is a synthetic structural analogue of N-acetylglutamate (NAG), and is indicated as adjunctive therapy for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency or maintenance therapy for treatment of chronic hyperammonemia due to NAGS deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114910</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for chlorpropamide (DIABINESE) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114912</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with melanoma, non-small cell lung cancer (NSCLC) or anaplastic thyroid cancer (ATC) and the BRAF V600E or V600K mutations; the drug is not indicated for treatment of patients with wild-type BRAF melanoma, NSCLC or ATC.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114913</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with certain types of cancer. The label also notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have a risk for developing hemolytic anemia, and that these patients should be closely observed when taking dabrafenib.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114923</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Lomitapide (JUXTAPID) is indicated as an adjunct to a low-fat diet and other lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (<em>LDLR</em>) are the most common cause of HoFH, however, mutations in other genes (such as <em>APOB</em>) can also lead to HoFH.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114926</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for mafenide (SULFAMYLON) mentions that fatal hemolytic anemia with disseminated intravascular coagulation has been reported following treatment with SULFAMYLON cream, possibly due to a glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency is a condition caused by variants in the <em>G6PD</em> gene which can be determined by enzymatic or genetic tests. However, the drug label does not specifically mention testing.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114928</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Mipomersen (KYNAMRO) is indicated as an adjunct to diet and lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (<em>LDLR</em>) are the most common cause of HoFH, however, mutations in other genes (such as <em>APOB</em>) can also lead to HoFH.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114930</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for omacetaxine (homoharringtonine; SYNRIBO) notes that it is intended for adults with chronic or accelerated phase chronic myeloid leukemia (CML). The majority of patients with CML are positive for the Philadelphia chromosome (<em>BCR-ABL1</em> gene fusion).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114931</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ponatinib (Iclusig) states that it is intended for adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, including those with the BCR-ABL T315I mutation. The majority of patients with CML are positive for the Philadelphia chromosome (<em>BCR-ABL1</em> gene fusion).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114941</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for pravastatin (PRAVACHOL) states that the drug is intended for patients with familial hypercholesterolemia (<em>Fredrickson</em> Type IIa), among other indications. Familial hypercholesterolemia is commonly caused by mutations in the <em>LDLR</em> (low density lipoprotein receptor) gene; pravastatin has only been evaluated in patients with heterozygous familial hypercholesterolemia (i.e. patients with only one abnormal copy of the <em>LDLR</em> gene).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166114944</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for regorafenib (STIVARGA) states that it is intended for patients with metastatic colorectal cancer who were previously given fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if they were RAS wild type, an anti-EGFR therapy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166115362</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Sodium nitrite is intended for sequential use with sodium thiosulfate, in order to treat acute and life-threatening cyanide poisoning. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are treated with sodium nitrite are at risk for a hemolytic crisis. Consideration should also be given for patients at increased risk for methemoglobinemia such as those with variants in CYB5R3.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166115363</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Succimer (CHEMET) is used for treating lead poisoning in pediatric patients with blood lead levels greater than 45 mcg/dL. The drug label notes that succimer has been used to treat five patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency without any adverse reactions.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166115365</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166119823</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for afatinib (GIOTRIF) states that it is indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations, among other indications.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166119824</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for belimumab (Benlysta) contains information regarding its mechanism of action for use in the treatment of systemuc lupus erythematosus (SLE). It is a human IgG1lambda that blocks binding of TNFSF13B to its receptor to inhibit B cell survival and reduce differentiation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166119825</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for carglumic acid (Carbaglu) states that it is indicated in the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) primary deficiency, among other indications.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166119826</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for dabrafenib (Tafinlar) states that it is indicated for patients with melanoma or non-small cell lung cancer with the BRAF V600 mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166120287</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for norelgestromin and ethinyl estradiol (EVRA) states that it is contraindicated in patients with known hereditary or acquired predisposition for venous thromboembolism, including Factor 5 Leiden (<em>F5</em>), antithrombin-III deficiency (<em>SERPINC1</em>), protein C deficiency (<em>PROC</em>) and protein S deficiency (<em>PROS</em>).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166120370</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for pioglitazone and glimepiride (Tandemact) states that caution should be taken in patients with G6PD deficiency as glimepiride is a sulfonylurea agent and a non-sulfonylurea alternative should be considered.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166121250</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for lomitapide (Lojuxta) states it is indicated only for use in adult patients with homozygous familial hypercholesterolaemia and that genetic conformation should be obtained when possible. Genetic tests include screening for variants in the LDLR, APOB and PCSK9 genes (see the <a rel="noopener noreferrer" href="http://www.ncbi.nlm.nih.gov/gtr/" target="_blank">Genetic Test Registry</a> for more information).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166121251</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for mercaptopurine (Xaluprine) states that starting or target doses should be lower in patients with reduced or absent TPMT enzyme activity, and that patients with mutated NUDT15 gene also generally require a dose reduction.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166121327</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for pegloticase (Krystexxa) states that screening in patients at higher risk for G6PD deficiency should be carried out prior to pegloticase treatment. It is contraindicated in these patients due to a higher risk of hemolysis and methemoglobinemia. <strong>Please note that as of June 2016 pegloticase (Krystexxa) has been <a rel="noopener noreferrer" href="https://www.ema.europa.eu/en/medicines/human/EPAR/krystexxa" target="_blank">withdrawn</a> from use in the European Union.</strong></p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166122067</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for ponatinib (Iclusig) states that indications of the drug include patients with Philadelphia chromosome positive (BCR-ABL1 gene fusion) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or patients who have the BCR-ABL T315I mutation, due to its mechanism of action as an inhibitor of BCR-ABL and inhibitor of mutant forms of the ABL kinase.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166122488</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for regorafenib (Stivarga) states that the hazard ratios for overall survival and progression-free survival were lower in patients with KRAS wild-type tumors as compared to KRAS mutant tumors. However, the EPAR does not comment on the significance of this difference.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166122547</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for trastuzumab emtansine (Kadcyla) contains information regarding indication of the drug in patients with HER2-positive (encoded by the <em>ERBB2</em> gene) breast cancer due to its mechanism of action, and HER2 positive status should be tested for by a validated method.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166122607</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Vortioxetine (BRINTELLIX) is indicated as a treatment for major depressive disorder. The FDA-approved drug label for vortioxetine notes that the maximum recommended dose in patients who are known CYP2D6 poor metabolizers is 10 mg/day.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166123409</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (P-gp, MDR1) in intestinal absorption and biliary secretion of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166123421</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for atazanavir (REYATAZ) states that co-administration with voriconazole and ritonavir is not recommended, and that if voriconazole treatment is required a patient's CYP2C19 genotype should be performed if feasible. If the patient has at least one functional CYP2C19 allele, close clinical monitoring for a loss of voriconazole and atazanvir efficacy is recommended.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166123529</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for atorvastatin states that an indication for the drug is familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor gene (<em>LDLR</em>).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166123530</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for azathioprine notes that individuals with certain TPMT genetic variations may be at increased risk of developing myelotoxicity. The insert also notes that this myelotoxicity could be exacerbated by co-administration of drugs that inhibit TPMT, such as aminosalicylic acid derivatives.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166123541</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for gefitinib (Iressa) states that patients should be tested for EGFR gene mutations prior to administration. It also discusses the role of CYP2D6 is the metabolism of gefitinib.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166123542</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>Imatinib is an inhibitor of the BCR-ABL tyrosine kinase that is created by the Philadelphia chromosome rearrangement. The PMDA package insert for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166123547</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for panitumumab (Vectibix) states that it is indicated for patients with wild-type <em>KRAS</em> colorectal cancer, and that patients should be selected based on <em>RAS</em> (<em>KRAS</em> and <em>NRAS</em>) mutation status.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166123548</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for rasburicase notes that foreign clinical studies have shown that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can have severe hemolytic reactions when administered rasburicase, and patients should be carefully screened for a family history of G6PD deficiency or other red blood cell enzyme defects.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166123552</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for valproic acid states that it is contraindicated in patients with known urea cycle disorders (UCDs), due to a risk for severe hyperammonemia. UCDs result from mutations in one of several genes, including ornithine transcarbamylase (OTC) deficiency and carbamoyl-phosphate synthetase 1 (CPS1) deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127629</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for afatinib (GIOTRIF) states that it is indicated for the treatment of patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s), including exon 19 deletions and the exon 21 L858R point mutation. A validated test is required to identify EGFR mutation status.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127631</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for aripiprazole (ABILIFY) notes that CYP2D6 poor metabolizers have approximately an 80% increase in aripiprazole exposure and approximately a 30% decrease in exposure to the active metabolite compared to CYP2D6 extensive metabolizers.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127634</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for atorvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous and heterozygous familial hypercholesterolemia, genetically determined conditions caused by mutations in the low density lipoprotein receptor (<em>LDLR</em>)</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127635</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for azathioprine notes that individuals with an inherited deficiency of the thiopurine methyltransferase (TPMT) enzyme may be at risk for developing myelosuppression when treated with the drug.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127640</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for boceprevir (VICTRELIS) contains information regarding a genetic variant near the IFNL3 gene (<em>IL28B</em>, <a href="http://localhost:8080/variant/PA166155468">rs12979860</a>, a C to T change) which is a strong predictor of response to peginterferon alfa-2b/ribavirin treatment.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127641</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for bosutinib (BOSULIF) states that it is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127648</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for cetuximab (ERBITUX) states that it is indicated for treatment of EGFR-expressing K-ras wild-type metastatic colorectal carcinoma.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127649</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for chlorpropamide notes that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127656</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for dabrafenib (TAFINLAR) states that it is indicated for treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127657</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for dapsone (ACZONE) notes that oral dapsone treatment can result in hemolysis and hemolytic anemia, particularly in patients who are glucose-6-phosphate dehydrogenase (G6PD)-deficient. However, for this topical formulation of the drug, a study showed no clinically relevant cases of hemolysis or anemia in G6PD-deficient individuals.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127661</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for dexlansoprazole (DEXILANT) notes that CYP2C19 intermediate and poor metabolizers generally have higher exposure to the drug as compared to extensive metabolizers.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127663</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for divalproex states that it is contraindicated in individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and suspected POLG-related disorders in children under 2 years old.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127665</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for divalproex states that it is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and in children under two years of age who are suspected of having a POLG-related disorder.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127667</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for efavirenz, emtricitabine and tenofovir (ATRIPLA) states that patients homozygous for the G516T genetic variant in CYP2B6 may have increased plasma exposure of the drug. However, the effect of this increase on the occurrence of adverse events is unclear.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127668</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for eltrombopag (REVOLADE) states that caution should be used when administering the drug to patients with risk factors for thromboembolism, such as Factor V Leiden mutation (<a href="http://localhost:8080/variant/PA166153554">rs6025</a> in <em>F5</em>) and antithrombin III deficiency (<em>SERPINC1</em>).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127669</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for erlotinib (TARCEVA) states that it is indicated for patients with non-small cell lung cancer (NSCLC) who have a confirmed activating EGFR mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127676</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for gefitinib (IRESSA) states that it is indicated for patients with activating EGFR mutations, and should not be used in those with EGFR mutation negative tumors.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127677</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>Glibenclamide (glyburide; GLYBE) belongs to a class of drugs known as sulfonylurea agents. The product monograph for glibenclamide states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127678</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>Glimepiride (AMARYL) belongs to a class of drugs known as sulfonylurea agents. The product monograph for glimepiride states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127682</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127684</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>Ivacaftor (KALYDECO) is indicated in cystic fibrosis patients 6 years and older who have one of the following variants in CFTR: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R or G970R, or in patients 18 years and older with the R117H variant. The product monograph also states that ivacaftor is not effective in patients homozygous for the F508del variant.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127688</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>Lomitapide (JUXTAPID) is indicated as an adjunct to a low-fat diet and other lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (<em>LDLR</em>) are the most common cause of HoFH, however, mutations in other genes (such as <em>APOB</em>) can also lead to HoFH.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127690</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for mercaptopurine (PURINETHOL) states that individuals who are TPMT deficient are at risk of developing life-threatening bone marrow suppression when receiving the drug, and that substantial dose reductions are usually required for these individuals.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127693</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for nilotinib (TASIGNA) states that it is indicated for patients with Philadelphia chromosome positive (<em>BCR-ABL1</em> fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug. The monograph also notes that patients homozygous for the UGT1A1*28 allele (<a href="http://localhost:8080/variant/PA166159020">rs8175347</a>; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127694</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for nitrofurantoin states that individuals with a glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at risk for hemolytic anemia when receiving the drug, and that it should be discontinued if the patient exhibits signs of hemolysis.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127695</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the <em>MTHFR</em> gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127699</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for panitumumab (VECTIBIX) states that it is indicated for patients with EGFR-expressing metastatic colorectal carcinoma (mCRC) with wild-type <em>KRAS</em>, and should not be used in patients with <em>KRAS</em>-mutant mCRC or for whom <em>KRAS</em> mutation status is unknown.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127702</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for primaquine states that caution should be used in individuals with glucose-6-phosphate dehydrogenase (<em>G6PD</em>) deficiency or NADH methemoglobin reductase (<em>CYB5R1-4</em>) deficiency due to the risk of hemolytic anemia and methemoglobinemia, respectively.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127705</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for quinine states that it is contraindicated in patients with G6PD deficiency. However, it makes no statements regarding testing for G6PD deficiency prior to treatment.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127707</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for rasburicase (FASTURTEC) states that patients at higher risk for G6PD deficiency (e.g. those of African or Mediterranean ancestry) be screened prior to starting treatment, due to the risk of severe hemolytic anemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127709</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for rosuvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (<em>LDLR</em>)</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127712</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for sodium phenylbutyrate (Pheburane) states that it is indicated for treatment of urea cycle disorders due to deficiencies of carbamylphosphate synthetase (<em>CPS1</em>), ornithine transcarbamylase (<em>OTC</em>) or argininosuccinate synthetase (<em>ASS1</em>).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127714</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for sulfadiazine states that it should be used in caution in patients who are deficient for glucose-6-phosphate dehydrogenase (G6PD) due to the risk for hemolysis. However, the monograph makes no mention of testing for G6PD deficiency prior to treatment.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127715</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for sulfamethoxazole and trimethoprim (SULFATRIM) states that hemolysis may occur in individuals taking the drug who are deficient in glucose-6-phosphate dehydrogenase (G6PD). However, it does not make any statements regarding testing for G6PD deficiency prior to treatment.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127716</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for sulfasalazine (SALAZOPYRIN) notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency should be closely monitored for signs of hemolytic anemia when receiving the drug. However, no statement is made regarding testing for G6PD deficiency prior to treatment.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127717</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for erythromycin and sulfisoxazole states that it is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, due to the risk for hemolysis. However, the monograph does not discuss testing for G6PD deficiency prior to treatment.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127720</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for thioguanine (LANVIS) notes that individuals with deficiency of the thiopurine methyltransferase (TPMT) enzyme may be at increased risk of developing myelosuppression when receiving the drug, and that testing for TPMT deficiency is available.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127722</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for trametinib (MEKINIST) states that it is indicated for patients with unresectable or metastatic melanoma with a BRAF V600 mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127726</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for valproic acid states that it is contraindicated in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG) or in patients with known urea cycle disorders, particularly ornithine transcarbamylase (OTC) deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127728</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for vemurafenib (ZELBORAF) states that it is indicated for the treatment of patients with BRAF V600 mutation-positive melanoma, and that it should not be used in patients with BRAF wild-type melanoma.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127729</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127731</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for vortioxetine (TRINTELLIX) states that the concentration of the drug is approximately 2 times higher in CYP2D6 poor metabolizers as compared to extensive metabolizers.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166127732</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for warfarin (COUMADIN) notes that patients carrying one or two copies of the CYP2C9*2 or *3 alleles may require a decreased mean daily warfarin dose, and have an increased bleeding risk, as compared to those homozygous for the CYP2C9*1 allele. Additionally, variations in the <em>VKORC1</em> gene, such as -1639G&gt;A, are also associated with changes in the dose requirement of warfarin.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166129450</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for trametinib (Mekinist) states that it is indicated for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation, Stage III melanoma with a BRAF V600 mutation following complete resection, or advanced non-small cell lung cancer with a BRAF V600 mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166129515</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Desflurane (SUPRANE) is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. The FDA-approved label warns that individuals with a genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively, if administered desflurane.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166129517</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for isoflurane (FORANE) warns that individuals with a genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively, if administered isoflurane.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166129525</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>Carglumic acid (Carbaglu) indicated for patients for the treatment of acute or chronic hyperammonemia due to deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166129527</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>Ponatinib (ICLUSIG) is indicated for adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including CML or Ph+ ALL that is T315I mutation positive. The majority of patients with CML are positive for the Philadelphia chromosome (<em>BCR-ABL1</em> gene fusion). The T315I mutation is known to cause resistance to other BCR-ABL kinase inhibitors.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166129528</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>Sodium nitrite is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning judged to be life-threatening. Patients with G6PD deficiency are at increased risk for hemolytic crisis when administered sodium nitrite; the product monograph notes that alternative therapeutic approaches should be considered in these patients. G6PD deficiency is a condition caused by variants in the <em>G6PD</em> gene which can be determined by enzymatic or genetic tests. However, the drug label does not specifically mention testing</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166131627</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for osimertinib (TAGRISSO) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, or those who have EGFR T790M mutations and whose disease has progressed on or after EGFR TKI therapy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166151853</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Nilotinib (Tasigna) is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 (<a href="http://localhost:8080/variant/PA166159020">rs8175347</a>) are at an increased risk of hyperbilirubinemia when taking nilotinib.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166151878</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (<em>ERBB2</em>). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166151881</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for rasburicase (Elitek) states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency. The label also states that It is unclear whether patients with NADH cytochrome b5 reductase (<em>CYB5R1, 2, 3, 4</em>) deficiency are at risk for methemoglobinemia or hemolytic anemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166151974</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for nilotinib (TASIGNA) notes that patients homozygous for the UGT1A1*28 allele (<a href="http://localhost:8080/variant/PA166159020">rs8175347</a>; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib.  This drug is indicated for patients with Philadelphia chromosome positive (BCR-ABL1 fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166152939</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ivacaftor and lumacaftor combination (ORKAMBI) states that it is indicated for treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the <em>F508del</em> mutation (rs113993960) in the <em>CFTR</em> gene.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166159064</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Elosulfase alfa (VIMIZIM) is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome. This disease results from deficiency or marked reduction of the galactosamine (N-acetyl)-6-sulfatase (GALNS) enzyme.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166159586</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The HCSC product monograph for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (Pgp, MDR1) in intestinal absorption of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166159707</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The HCSC for atazanavir (Reyataz) contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir: atazanavir exposure is expected to be decreased and voriconazole exposure is expected to be increased in patients who do not have a functional CYP2C19 allele.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166159938</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>Belimumab (BENLYSTA) is a human IgG1λ monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166159962</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Although the alirocumab (PRALUENT) drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of adults with heterozygous familial hypercholesterolemia. Familial hypercholesterolemia is commonly caused by mutations in the <em>LDLR</em> gene.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160021</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for cabozantinib (COMETRIQ) states that RET mutation status was determined in clinical studies of the drug, and that the drug inhibits the activity of the RET protein.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160039</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for evolocumab (REPATHA) states that it is indicated for the treatment of heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia is commonly caused by mutations in the <em>LDLR</em> gene.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160046</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for cobimetinib (COTELLIC) states that it is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160051</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for alectinib (ALECENSA) states that it is indicated for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160052</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for palonosetron (ALOXI) states that there is no significant difference in clinical pharmacokinetic parameters between CYP2D6 poor and extensive metabolizers.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160056</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for cholic acid (CHOLBAM) states that one of the indications of the drug is for bile acid synthesis disorders due to single enzyme defects. This includes deficiencies in the 3β-HSD (<em>HSD3B7</em>), AKR1D1 (<em>AKR1D1</em>), CYP27A1 (<em>CYP27A1</em>), AMACR (<em>AMACR</em>), and CYP7A1 (<em>CYP7A1</em>) enzymes.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160061</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for dinutuximab (UNITUXIN) provides information on the MYCN status of patients in a clinical study of the drug.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160121</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for nivolumab (OPDIVO) previously stated that it is indicated for the treatment of patients with BRAF V600 wild-type or BRAF V600 mutation-positive unresectable or metastatic melanoma as a single agent, among other indications. The label now indicates for unresectable or metastatic melanoma and does not define by BRAF mutation, although there is discussion of BRAF in the different clinical studies.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160133</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for palbociclib (IBRANCE) states that it is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with either an aromatase inhibitor or fulvestrant.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160274</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for cetuximab (ERBITUX) states that it is indicated for individuals with epidermal growth factor receptor (EGFR)-positive, progressive or recurrent colorectal cancer that is refractory and inoperable. It also notes that <em>K-Ras</em> mutational status should be considered when selecting patients.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160672</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for tamsulosin (FLOMAX) states that it should be used with caution in CYP2D6 poor metabolizers, particularly at doses higher than 0.4 mg, due to the potential for a significant increase in exposure of the drug.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160683</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for dapsone (PROTOGEN) states that hemolysis may occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160710</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for erlotinib states that it is indicated for recurrent and/or advanced inoperable non-small cell lung cancer that is positive for an EGFR gene mutation and has not been previously treated with chemotherapy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160718</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for methylene blue states that patients with glucose-6-phosphate dehydrogenase (<em>G6PD</em>) deficiency or <a rel="noopener noreferrer" href="http://www.omim.org/entry/250700" target="_blank">NADPH reductase (<em>BLVRB</em>) deficiency</a> may have exacerbation of methemoglobinemia or hemolysis following administration.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160719</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for nalidixic acid states that patients with G6PD deficiency are at increased risk of hemolytic anemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160847</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for sulfadiazine (GEBEN) states that hemolysis may occur in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160848</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for sulfamethoxazole and trimethoprim (DAIPHEN) states that hemolysis may occur in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160849</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for sulfasalazine (Azulfidine) states that hemolysis may occur in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160851</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>The PMDA package insert for vemurafenib (ZELBORAF) states that it is indicated for patients with unresectable, refractory melanoma with BRAF gene mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166160854</span>
                </td>
                <td>
                    <span>Pharmaceuticals and Medical Devices Agency, Japan</span>
                </td>
                <td>
                    <span><p>MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the PMDA package insert warns that hemolytic reactions are possible in those with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166163417</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>EPCLUSA (sofosbuvir and velpatasvir) is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166163420</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Venetoclax (VENCLEXTA) is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. The label also notes whether mutation analyses detected mutations in the <em>TP53</em>, <em>IDH1</em>, <em>IDH2</em>, <em>FLT3</em> and <em>NPM1</em> genes. The label states that the 11q deletion was detected in 32% of patients in the MURANO study.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166163433</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for eteplirsen (EXONDYS 51) states that it is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166169877</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for avelumab (BAVENCIO) states that it is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of metastatic Merkel cell carcinoma and locally advanced or metastatic urothelial carcinoma. PD-L1 is encoded by the <em>CD274</em> gene.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166169880</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Cerliponase alfa (BRINEURA) is indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166169884</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for durvalumab (IMFINZI) states that it is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma or Stage III non-small cell lung cancer, both with certain qualifications. PD-L1 is encoded by the <em>CD274</em> gene.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166169912</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Enflurane (ETHRANE) is an inhalational anesthetic. The FDA-approved label warns that individuals with known or suspected genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166169918</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for midostaurin (RYDAPT) states that it is indicated for the treatment of adult patients with acute myeloid leukemia that is FLT3 mutation-positive as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170048</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Ribociclib (KISQALI) is indicated in combination with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170929</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. The label also notes the potential clinical importance of considering CYP2D6 phenotype, though CYP2D6 testing is not mentioned.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170931</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for midostaurin (RYDAPT) states that it is indicated for the treatment of adult patients with acute myeloid leukemia that is FLT3 mutation-positive as detected by an FDA-approved test. The label also notes the percentage of patients with an NPM1 mutation or KIT D816V mutation in clinical studies.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170932</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for pembrolizumab (KEYTRUDA) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (CD274) as detected by an FDA-approved test. The label also mentions BRAF V600 mutations.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170933</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Pertuzumab (PERJETA) is a targeted antibody drug designed to bind to ERBB2 (HER2). The drug label notes that the pathological complete response rate was lower in patients with hormone receptor-positive tumors compared with hormone receptor-negative tumors.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170934</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for primaquine states that G6PD testing has to be performed before using the drug, and that it should not be prescribed for patients with severe G6PD deficiency. The label also notes that individuals with a family or personal history of nicotinamide adenine dinucleotide (NADH) methemoglobin reductase (<em>CYB5R1-4</em>) deficiency should be observed closely.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170936</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Tamoxifen (SOLTAMOX) is indicated for the treatment of breast cancer. A clinical trial showed no benefit of screening for Factor V Leiden (F5) or Prothrombin (F2) mutations when treating with tamoxifen.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170937</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that patients with a known history of G6PD deficiency were excluded from some clinical trials.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170938</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that dabrafenib may promote growth and development of malignancies with activitation of RAS (<em>HRAS</em>, <em>KRAS</em>, <em>NRAS</em>).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170957</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Vemurafenib (ZELBORAF) is a kinase inhibitor used to treat patients with unresectable or metastatic melanoma in cases where the BRAF V600E mutation is found by an FDA-approved test. The label notes that the drug may promote malignancies associated with activation of RAS (<em>HRAS</em>, <em>KRAS</em>, <em>NRAS</em>).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166170958</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for valproic acid (Depakene) states that it is contraindicated in individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and suspected POLG-related disorders in children under 2 years old.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166177486</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Enasidenib (IDHIFA) is an isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated for the treatment of adult patients with acute myeloid leukemia with an IDH2 mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166177509</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Formoterol (PERFOROMIST) is indicated in patients with chronic obstructive pulmonary disease (COPD). The label notes that the effect of patients with CYP2D6 or CYP2C19 deficiency on formoterol exposure has not been adequately explored.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166177516</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Neratinib (NERLYNX) is indicated for the treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166177521</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Umeclidinium (INCRUSE ELLIPTA) is indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD). The label notes that there was no clinically meaningful difference in exposure to the drug between patients who were CYP2D6 poor metabolizers and those who were CYP2D6 intermediate, extensive and ultrarapid metabolizers.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166178724</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Neratinib (NERLYNX) is indicated for the treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer. The label notes the percentages of patients in clinical studies who had hormone receptor positive disease.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166179847</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ivacaftor and tezacaftor combination (SYMDEKO) states that it is indicated for treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the <em>CFTR</em> F508del mutation (rs113993960) or have at least one mutation in the <em>CFTR</em> gene that is responsive to ivacaftor and tezacaftor according to <em>in vitro</em> and/or clinical data.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166179855</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for avatrombopag (DOPTELET) states that the risk for thrombosis should be considered in patients with risk factors for thromboembolism, including genetic prothrombotic conditions such as Factor V Leiden (F5), Prothrombin 20210A (F2), Antithrombin deficiency (SERPINC1) or Protein C (PROC) or S (PROS1) deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166179870</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for binimetinib (MEKTOVI) states that it is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166179871</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Binimetinib (MEKTOVI) states is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. The FDA-approved drug label also states that UGT1A1 genotype does not have a clinically important effect on binimetinib exposure.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166179878</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for encorafenib (BRAFTOVI) states that it is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182021</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for amifampridine phosphate (FIRDAPSE) states that NAT2 poor metabolizers have higher concentrations of the drug as compared to normal metabolizers, and that the drug should be initiated at the lowest recommended starting dosage in these patients.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182280</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for dacomitinib (VIZIMPRO) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutations as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182721</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for erdafitinib (BALVERSA) states that it is a kinase inhibitor indicated for the treatment of adult patients
with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and progressed during or following at least one line of prior platinum-containing chemotherapy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182722</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for erdafitinib (BALVERSA) states that it is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and progressed during or following at least one line of prior platinum-containing chemotherapy. The label further states that erdafitinib plasma concentrations were predicted to be higher in patients with the CYP2C9*3/*3 genotype and to monitor for increased adverse reactions in patients who are known or suspected to have CYP2C9*3/*3 genotype.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182725</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for eribulin (HALAVEN) states that it is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182726</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Rivaroxaban (XARELTO) is an anticoagulant with several indications, including for the reduction of risk of recurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). In a study of the efficacy of rivaroxaban in reducing the risk of recurrence of DVT or PE, mutations in F5 are mentioned as a risk factor for recurrence of DVT or PE.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182727</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ivosidenib (TIBSOVO) states that it is indicated for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182728</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ropivacaine (NAROPIN) states that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia (associated with variants in CYB5R3) are more susceptible to developing methemoglobinemia in association with use of local anesthetics.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182737</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for lidocaine and tetracaine (SYNERA) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for methemoglobinemia. Close monitoring for symptoms and signs of methemoglobinemia is recommended in this subset of patients.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182739</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for tafenoquine states that G6PD testing must be performed before prescribing the drug, and that tafenoquine is contraindicated in patients with G6PD deficiency or of unknown G6PD status.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182741</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for articaine and epinephrine (ORABLOC) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182746</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ceftriaxone (ROCEPHIN) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182749</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for lusutrombopag (MULPLETA) states that the potential increased risk for thrombosis should be considered in patients with risk factors for thromboembolism, including genetic prothrombotic conditions such as Factor V Leiden (F5), Prothrombin 20210A (F2), Antithrombin deficiency (SERPINC1) or Protein C (PROC) or S (PROS1) deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182750</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for toremifene (FARESTON) states that it is indicated for the treatment of estrogen-receptor positive or unknown metastatic breast cancer.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182751</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for mepivacaine states that patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia may be more susceptible to developing clinical manifestations of methemoglobinemia. Close monitoring for symptoms and signs of methemoglobinemia is recommended in this subset of patients.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182759</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for chloroprocaine (Nesacaine) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182769</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for hydroxychloroquine (PLAQUENIL) states that it should be administered with caution in patients having glucose-6-phosphate dehydrogenase (G6PD) deficiency and that hemolysis was reported in individuals with
glucose-6-phosphate dehydrogenase (G6PD) deficiency. The CDC Information for Clinicians on Therapeutic Options for COVID-19 Patients discusses hydroxychloroquine but does not discuss testing for G6PD deficiency in this context.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182786</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for tolazamide states that, due to the risk of hemolytic anemia, caution should be used when administering tolazamide to patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182787</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for tolbutamide states that, due to the risk of hemolytic anemia, caution should be used when administering tolbutamide to patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182788</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The HCSC-approved product monograph for tolbutamide (APO-TOLBUTAMIDE) states that, due to the risk of hemolytic anemia, caution should be used when administering tolbutamide to patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182789</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) states that toremifene (FARESTON) is not recommended for patients with metastatic breast cancer who have estrogen receptor negative tumors.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182925</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for amifampridine (FIRDAPSE) states that exposure to the drug is influenced by the acetylation activity of NAT enzymes and the NAT2 genotype, and that slow acetylators experienced more adverse reactions as compared to fast acetylators.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182928</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for binimetinib (Mektovi) states that it is indicated in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182929</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for binimetinib (Mektovi) states that it is indicated in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The EPAR also states that there is no apparent relationship observed between binimetinib exposure and UGT1A1 mutation status.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182934</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for cerliponase alfa (Brineura) states that it is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182940</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for cholic acid (Orphacol) states that it is indicated for the treatment of inborn errors in primary bile acid synthesis due to deficiencies in the proteins encoded by the <em>HSD3B7</em> and <em>AKR1D1</em> genes. The EPAR for cholic acid (Kolbam) is indicated for deficiencies in the proteins encoded by the <em>CYP27A1</em>, <em>AMACR</em> and <em>CYP7A1</em> genes.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182941</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for cobimetinib (Cotellic) states that it is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutations.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182942</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for dacomitinib (Vizimpro) states that it is indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations,</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182947</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for elosulfase alfa (Vimizim) states that it is indicated for patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome. This disease results from deficiency or marked reduction of the galactosamine (N-acetyl)-6-sulfatase (GALNS) enzyme.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182948</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for encorafenib (Braftovi) states that it is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182951</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for glibenclamide (AMGLIDIA) states that it should not be prescribed in patients with G6PD deficiency, and that use of an alternative treatment is strongly recommended.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182953</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for ivacaftor and lumacaftor (Orkambi) states that it is indicated for the treatment of cystic fibrosis in patients aged 6 years and older who are homozygous for the <em>F508del</em> mutation in the <em>CFTR</em> gene.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182954</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for ivacaftor and tezacaftor (Symkevi) states that it is indicated for the treatment of patients with cystic fibrosis aged 12 years and older who are homozygous for the <em>F508del</em> mutation or who are heterozygous for the <em>F508del</em> mutation and have one of the following mutations: <em>P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A-&gt;G, S945L, S977F, R1070W, D1152H, 2789+5G-&gt;A, 3272-26A-&gt;G, 3849+10kbC-&gt;T</em>.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166182961</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Duvelisib (COPIKTRA) is indicated for various leukemia types and the FDA label mentions that some patients had the 17p chromosomal deletion.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183183</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for lidocaine and prilocaine (Fortacin) states that patients or their partner with G6PD deficiency are more susceptible to methemoglobinemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183243</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for olaparib (Lynparza) in 50 mg hard capsules states that it is indicated for treatment of BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Olaparib (Lynparza) in 100 or 150 mg film-coated tablets is indicated for patients with germline <em>BRCA1/2</em>-mutations with HER2 negative breast cancer, among other indications.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183246</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for osimertinib (TAGRISSO) states that it is indicated for the treatment of adult patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations or EGFR T790M mutation.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183247</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for palbociclib (IBRANCE) states that it is indicated for the treatment of hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183249</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for pembrolizumab (KEYTRUDA) states that it is indicated for the treatment of certain cancers whose tumors express PD-L1 (<em>CD274</em>), among other indications.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183425</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for talazoparib (Talzenna) states that it is indicated as a monotherapy for the treatment of adult patients with germline BRCA1 or BRCA2 mutations, who have HER2-negative locally advanced or metastatic breast cancer.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183782</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for aspirin (Aspirin Cardio 100/300, Aspirin, Aspirin-C) states that acetylsalicylic acid could induce hemolysis or hemolytic anemia in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183786</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for amlodipine, atorvastatin and perindopril arginine (Triveram) states that patients with G6PD deficiency may experience hemolytic anemia. Additionally, patients with the SLCO1B1 rs4149056 CC genotype may have higher atorvastatin exposure which may increase the risk of rhabdomyolysis.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183789</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for metabutethamin (Alcacyl® 500 Instant-Pulver) states that patients with G6PD deficiency may have increased risk of adverse events to metabutethamin and caution is advised.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166183901</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for moxifloxacin (Avalox) states that moxifloxacin should be used with caution in patients with G6PD deficiency.
.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184108</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug labels for fluorouracil/salicylic acid (Actikerall and Verrumal) state that, where appropriate, DPYD activity levels should be determined prior to fluorouracil treatment.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184110</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug labels for vitamin C (Streuli, Callimon and Revitalose) state that high doses of vitamin C should be avoided in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184112</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for azathioprine (Imurek) states that a dose reduction is generally required for patients carrying NUDT15 variants and notes that patients with TPMT deficiency are sensitive to the myelosuppressive effect of azathioprine.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184113</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for bisoprolol fumarate/perindopril arginine (Cosyrel) states that patients with G6PD deficiency may experience hemolytic anemia as a result of bisoprolol fumarate/perindopril arginine treatment.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184114</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for capecitabine (Xeloda) states that capecitabine is contraindicated in patients with low or no DPYD activity. Patients with partial DPYD deficiency may be given capecitabine at a significantly reduced dose if the benefit of the drug is deemed to outweigh the risks.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184117</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for carbasalate calcium (Alcacyl) states that carbasalate calcium shoudl be used with caution in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184120</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for quinine (Chininsulfat 250 Hänseler) states that quinine is contraindicated in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184121</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for chloroquine (Nivaquine) states that chloroquine is contraindicated in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184122</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for ciprofloxacin (Ciproxin) states that ciprofloxacin should be used with caution in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184128</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for acetaminophen/codeine (Co-Dafalgan) states that acetaminophen (paracetamol) should be used with caution in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184155</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for nitrofurantoin (Uvamin retard) states that breastfeeding of infants suspected or known to suffer from erythrocyte enzyme deficiency (including G6PD deficiency) should be avoided as traces of nitrofurantoin are found in breast milk.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184156</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for norfloxacin (Norsol) states that patients with G6PD deficiency may experience hemolytic anemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184157</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for ofloxacin (Tarivid) states that ofloxacin should be used with caution in patients with G6PD deficiency due to increased risk of hemolytic reactions.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184237</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for vitamin B complex with vitamin C (Begrocit) states that overdose of vitamin C can cause hemolysis in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184286</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for perindopril (COVERSUM N 5 mg/10 mg) states that patients with congenital G6PD deficiency may have risk for haemolytic anaemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184381</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for prilocaine (Oraqix) cautions that patients with G6PD may be at increased risk for methemoglobinemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184389</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug labels for sulfadiazin-silber (Flammazine) and Sulfadiazin-Silber, Kombinationen (Ialugen Plus) has a caution for use in patients with known or suspected G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184390</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for sulfamethoxazole and trimethoprim (Bactrim) cautions about use of the drug in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184391</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for sulfasalazine (Salazopyrin) states that the drug is contraindicated in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184403</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for rasburicase (Fasturtec) states that rasburicase is contraindicated in patients with G6PD deficiency due to risk of hemolytic anaemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184423</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for Thrombozytenaggregationshemmer, exkl. Heparin (DuoPlavin 75/100 mg) cautions about use in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184424</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for thioguanine (Lanvis) cautions about use in patients with a congenital deficiency of the enzyme thiopurine methyltransferase (TPMT).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184428</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for sertindole (Serdolect) states that sertindole is extensively metabolized by the CYP2D6 and CYP3A, and sertidole concentration may be affected in patients who are CYP2D6 poor metabolizers and in patients simultaneously taking drugs that are CYP2C6 or CYP3A inhibitors.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184449</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for flucytosine (Ancotil) cautions about risk for toxicity of flucytosine in patients with DPYD deficiency if nucleoside analogues have been given and states that DPYD testing is indicated. It does not discuss testing in patients receiving flucytosine only.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184450</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for fluorouracil (Efudix) requires DPYD testing in patients receiving fluorouracil who have also been treated with brivudine or other nucleoside analogues.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184451</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for fluorouracil (Fluorouracil Labatec) cautions about increased toxicity in patients with the 2R/2R and 2R/3R genotypes in the TYMS gene promoter relative to that of 3R/3R individuals.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184456</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for glibenclamide (Daonil) states that caution should be used when treating patients with G6PD deficiency with glibenclamide as they are at increased risk for hemolytic anemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184457</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for gliclazide (Diamicron) states that caution should be used when treating patients with G6PD deficiency with gliclazide as they are at increased risk for hemolytic anemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184458</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for glimepiride (Amaryl) states that caution should be used when treating patients with G6PD deficiency with glimepiride as they are at increased risk for hemolytic anemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184459</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for Glyceroltrinitrat (Deponit) states that caution should be used when treating patients with G6PD deficiency with glycerol trinitrate (also known as nitroglycerin) due to reduced metabolism.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184461</span>
                </td>
                <td>
                    <span>Swissmedic</span>
                </td>
                <td>
                    <span><p>The Swiss drug label for hydroxychloroquine (Plaquenil) states that this drug is contraindicated in patients with G6PD deficiency.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184524</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for alpelisib (PIQRAY) states that it is indicated for the treatment of patients with hormone receptor positive, HER-2 negative (ERBB2 negative) and PIK3CA-mutated breast neoplasms.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184560</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ramucirumab (CYRAMZA) states that it is indicated for patients with EGFR or ALK
genomic tumor aberrations who have had disease progression on FDA-approved therapy for these aberrations prior to receiving
CYRAMZA. Ramucirumab is targeted against human vascular endothelial growth factor receptor 2 (VEGFR2) coded for by <em>KDR</em>, although any testing for variants in KDR is not discussed in the drug label. EGFR is listed on the FDA table but ALK is not.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184561</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for ramucirumab (CYRAMZA) states that KRAS status testing was used to stratify patients in the RAISE (NCT01183780) clinical trial of ramucirumab in metastatic colorectal cancer.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184565</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA label for tafamidis (VYNDAQEL) and (VYNDAMAX) states is it indicated for the treatment of the cardiomyopathy of wild type or
hereditary transthyretin-mediated amyloidosis (ATTR-CM).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184636</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for tipiracil / trifluridine (Lonsurf) states that it is indicated for patients who have failed other targeted therapies including those for KRAS negative metastatic colorectal cancer and HER2 positive (ERBB2) metastatic gastric or gastroesophageal junction cancers. Therefore testing was required for those prior therapies.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166184637</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for Oxymetazoline and Tetracaine (KOVANAZE) states that patients with G6PD deficiency or congenital methemoglobinemia may be at increased risk for methemoglobinemia when treated with this drug. There is also a warning for pseudocholinesterase deficiency (BCHE) and risk for toxicity which is not listed on the FDA biomarker table.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166190261</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Estradiol / progesterone (BIJUVA) is a combination of an estrogen and progesterone indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause. It is contraindicated in patients with known protein C (PROC), protein S (PROS1), or antithrombin (SERPINC1) deficiency, or other known thrombophilic disorders.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166190701</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Givosiran (GIVLAARI) is an aminolevulinate synthase 1-directed small interfering RNA indicated for the treatment of adults with acute hepatic porphyria (AHP). The efficacy of GIVLAARI was evaluated in the ENVISION trial in patients with acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP). Mutations in CPOX, HMBS and PPOX genes have been linked to these autosomal dominant disorders.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166190741</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Golodirsen (VYONDYS 53) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166191561</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for nivolumab (OPDIVO) stated that it is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of a variety of cancers, including  patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test. Nivolumab is approved as first line therapy for patients with no EGFR and ALK genomic tumor aberrations and for patients with EGFR and ALK genomic tumor aberrations who have disease progression on FDA-approved therapies. It is also approved for   adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as a single agent or in combination with ipilimumab.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166191581</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Ipilimumab (Yervoy) is a human cytotoxic T-lymphocyte antigen 4-blocking antibody indicated for a few cancer types including microsatellte instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer, as well as metastatic non-small cell lung cancer expressing PD-L1 (≥1%), and metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166223861</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for bupropion (WELLBUTRIN) states that bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166223902</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA label for alglucosidase alfa (LUMIZYME) states that LUMIZYME® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase (GAA) deficiency)</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166223941</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA label for avapritinib (AYVAKIT) states that avapritinib is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166224202</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA label for capmatinib (TABRECTA) states that capmatinib is a kinase inhibitor to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166224341</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for encorafenib (BRAFTOVI) states that BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms. FDA recommends monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies and discontinue BRAFTOVI for RAS mutation-positive non-cutaneous malignancies.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166227101</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The FDA label for alglucosidase alfa (Myozyme) states that Myozyme is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase (GAA) deficiency)</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166227121</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The HCSC label for alglucosidase alfa (Myozyme) states that MYOZYME  is indicated for use in patients with Pompe’s Disease (GAA deficiency).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166227141</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for ramucirumab (Cyrazma) states that it is indicated for first-line treatment of metastatic non-small cell lung cancer with activating EGFR mutations, among other indications.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166227161</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for ramucirumab states that tumor KRAS status testing was used to stratify patients in the RAISE (NCT01183780) clinical trial of ramucirumab in metastatic colorectal cancer.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166227181</span>
                </td>
                <td>
                    <span>European Medicines Agency</span>
                </td>
                <td>
                    <span><p>The EMA European Public Assessment Report (EPAR) for alpelisib (Piqray) states that it is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166227201</span>
                </td>
                <td>
                    <span>Health Canada Santé Canada</span>
                </td>
                <td>
                    <span><p>The product monograph for alpelisib (Piqray) states that it is indicated, in combination with fulvestrant, for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166234723</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for atorvastatin (LIPITOR) states that atorvastatin exposure may be increased by drug interactions due to inhibition of CYP3A4 and/or transporters (e.g., breast cancer resistant protein (BCRP), organic anion-transporting polypeptide (OATP1B1 (SLCO1B1)/OATP1B3) and P-glycoprotein (P-gp (ABCB1))), resulting in an increased risk of myopathy and rhabdomyolysis.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166234761</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for simvastatin (ZOCOR) states that simvastatin acid is a substrate of the transport protein OATP1B1 (SLCO1B1) and concomitant administration of medicinal products that are inhibitors of the transport protein OATP1B1 may lead to increased plasma concentrations of simvastatin acid and an increased risk of myopathy.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166235261</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for anakinra (KINERET) states that anakinra is an interleukin-1 receptor antagonist indicated for rheumatoid arthritis, cryopyrin-Associated Periodic Syndromes (CAPS) (treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)) and deficiency of Interleukin-1 Receptor Antagonist (DIRA). Spontaneous mutations in the CIAS1/NLRP3 gene have been identified in a majority of patients with cryopyrin-associated periodic syndromes such as NOMID.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166235361</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for lumasiran (OXLUMO) implies that testing for AGXT gene mutation is required since the drug is only approved for treatment of primary hyperoxaluria type 1, a disorder resulting from variants in AGXT, in pediatric and adult patients.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166235441</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for bupivacaine (Marcaine) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166235601</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for lonafarnib (ZOKINVY) states that ZOKINVY is indicated for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166235881</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Margetuximab (MARGENZA) is FDA-approved for treatment of adult patients with metastatic HER2-positive breast cancer. HER2 is a name for the product of the gene <a href="http://localhost:8080/gene/PA27844">ERBB2</a>.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166235941</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved drug label for setmelanotide (IMCIVREE) states that is a melanocortin 4 (MC4) receptor agonist indicated for chronic
weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166236241</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>Satralizumab (ENSPRYNG) is an interleukin-6 receptor (<a href="http://localhost:8080/gene/PA29835">IL6R</a>) antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. The FDA biomarker table lists the aquaporin gene (<a href="http://localhost:8080/gene/PA24922">AQP4</a>).</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166236521</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for viltolarsen (VILTEPSO) states that it is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.</p>
</span>
                </td>
            </tr>
        
            <tr>
                <td>
                    <span>PA166238981</span>
                </td>
                <td>
                    <span>U.S. Food and Drug Administration</span>
                </td>
                <td>
                    <span><p>The FDA-approved label for conjugated synthetic estrogens, A (CENESTIN) states that it is contraindicated for use in patients with protein C, protein S, or antithrombin deficiency. These proteins are encoded by <em>PROC</em>, <em>PROS1</em>, and <em>SERPINC1</em>, respectively.</p>
</span>
                </td>
            </tr>
        
    </tbody></table>
</div>
</section><remove-web-limits-iqxin id="rwl-iqxin" class="rwl-exempt" style="position: fixed; top: 0px; left: 0px;"><qxinbutton type="qxinbutton" id="rwl-setbtn"> set </qxinbutton> <lalala style="cursor:move; font-size:12px;">限制解除</lalala> <input type="checkbox" name="" id="black_node"><style type="text/css">#rwl-iqxin{position:fixed;transform:translate(-95px,0);width:85px;height:25px;font-size:12px;font-weight: 500;font-family:Verdana, Arial, '宋体';color:#fff;background:#333;z-index:2147483647;margin: 0;opacity:0.05;transition:0.3s;overflow:hidden;user-select:none;text-align:center;white-space:nowrap;line-height:25px;padding:0 16px;border:1px solid #ccc;border-width:1px 1px 1px 0;border-bottom-right-radius:5px;box-sizing: content-box;}#rwl-iqxin input{margin: 0;padding: 0;vertical-align:middle;-webkit-appearance:checkbox;-moz-appearance:checkbox;position: static;clip: auto;opacity: 1;cursor: pointer;}#rwl-iqxin.rwl-active-iqxin{left: 0px;transform:translate(0,0);opacity: 0.9;height: 32px;line-height: 32px}#rwl-iqxin label{margin:0;padding:0;font-weight:500;}#rwl-iqxin #rwl-setbtn{margin: 0 4px 0 0;padding: 0 0 0 4px;border: none;border-radius: 2px;cursor: pointer;background: #fff;color: #000;} </style></remove-web-limits-iqxin>



<footer class="footer">
    DST Group 4
    Precision Medicine Matching System
</footer>
<script type="text/javascript" src="./Precision Medicine Matching System_files/jquery-1.8.3.min.js.下载"></script>
<script type="text/javascript" src="./Precision Medicine Matching System_files/common.js.下载"></script>
<script type="text/javascript" src="./Precision Medicine Matching System_files/WdatePicker.js.下载"></script>


<script type="text/javascript" src="./Precision Medicine Matching System_files/userlist.js.下载"></script>

<script>mendeleyWebImporter = {
  downloadPdfs(t) { return this._call('downloadPdfs', [t]); },
  open() { return this._call('open', []); },
  _call(methodName, methodArgs) {
    const id = Math.random();
    window.postMessage({ id, token: '0.27345167819038485', methodName, methodArgs }, 'http://localhost:8080');
    return new Promise(resolve => {
      const listener = window.addEventListener('message', event => {
        const data = event.data;
        if (typeof data !== 'object' || !('result' in data) || data.id !== id) return;
        window.removeEventListener('message', listener);
        resolve(data.result);
      });
    });
  }
};</script><div style="position: absolute; z-index: 19700; top: -1970px; left: -1970px;"><iframe style="width: 186px; height: 198px;" src="./Precision Medicine Matching System_files/My97DatePicker.html" frameborder="0" border="0" scrolling="no"></iframe></div></body></html>